Can a once-weekly TB pill safely mix with HIV treatment in kids?

NCT ID NCT06281834

Recruiting now Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial investigates how a weekly TB prevention regimen (rifapentine and isoniazid) affects levels of the HIV drug dolutegravir in children living with HIV. Researchers will measure drug concentrations in the blood to see if the combination remains safe and effective. The study includes children from 4 weeks to under 12 years old who are stable on HIV treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of rifapentine and isoniazid (3HP) for TB prevention, given alongside standard HIV treatment with dolutegravir
What this could lead to: If successful, this could help establish safe dosing guidelines for combining TB prevention with HIV treatment in young children, potentially reducing TB-related deaths.
What could go wrong: This is a small, early-phase study focused on drug levels, not on clinical outcomes. Drug interactions may lower dolutegravir effectiveness or increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LATENT TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease latent tuberculosis infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LATENT TUBERCULOSIS PEDIATRIC HIV INFECTION

Contacts and locations

Locations

University College Hospital
RECRUITING

Ibadan, Oyo State, Nigeria, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.